Today, on February 14, IBEC organized the roundtable “Challenges in Innovation in Personalized Medicine and Emerging Therapies.” The event is part of Barcelona Health Innovation Week, organized by Biocat. It fostered a dialogue where experts from diverse fields shared their perspectives on identifying opportunities to propel the utilization of new technologies in the healthcare sector.
This week, from February 12 to 15, Barcelona Health Innovation Week is taking place. It is an event organized by Biocat dedicated to innovation, acceleration, technology, and the transformation of healthcare. Through face-to-face sessions, online seminars, talks, and debates, it enables healthcare organizations and companies to assert their presence in the market, showcase their latest innovations, and connect with their audience.
Within the framework of this event, today saw the roundtable “Challenges in Innovation in Personalized Medicine and Emerging Therapies,” organized by IBEC, coordinator of the Complementary Plan for Biotechnology applied to Health. Its objective was to reflect on the challenge of achieving clinical translation of basic discoveries and to explore fundamental issues related to scalability and access to emerging therapies.
The event was led by Josep Samitier, Director of IBEC and Coordinator of the Complementary Plan for Biotechnology Applied to Health. It provided a platform for experts from different fields to share their perspectives on identifying opportunities to promote the use of new technologies in healthcare. The ensuing discussion was highly engaging and allowed for exploration of current challenges in the field, including collaboration, clinical translation, scalability, cost, and equitable access.
Society is calling on us to address health issues, including access to healthcare and equity. In this event, we are committed to exploring innovative and collaborative solutions to tackle these fundamental challenges.
Josep Samitier
Among the guest speakers was Samuel Sánchez, IBEC Principal Investigator, founder of the start-up Nanobots Therapeutics, and a member of the technical committee of the Complementary Plan. Sánchez emphasized the importance of creating alliances with both the public administration and businesses to facilitate the translation of research into clinical innovation.
The roundtable also featured Laia Arnal, Director General of Knowledge Transfer and Society at the Department of Research and Universities of the Catalan Government; Joël Jean-Mairet, Managing Partner and Co-founder of Ysios Capital and a member of the industrial committee of the Supplementary Plan; Isabel Amat, Global Head of Innovation and Pipeline Management at Reig Jofré; and Miquel Rodriguez, Manager of Economic Promotion at Barcelona City Council.
Activity organized by IBEC, coordinator of the Complementary Plan for Biotechnology Applied to Health – an initiative focused on the development of tools for diagnosis, prognosis, and advanced therapies in personalized and precision medicine.
